2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107997
    TAP311 1149362-88-8 98%
    TAP311 is a cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 62 nM.
    TAP311
  • HY-108774
    Rosuvastatin zinc salt 953412-08-3 98%
    Rosuvastatin zinc salt (Rosuvastatin zinc) is a zinc-containing form of Rosuvastatin (HY-17504A). Rosuvastatin is a HMG-CoA reductase inhibitor and can be used for atherosclerosis research.
    Rosuvastatin zinc salt
  • HY-110021
    Fenoldopam hydrochloride 181217-39-0 98%
    Fenoldopam (SKF 82526) hydrochloride is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam hydrochloride shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis.
    Fenoldopam hydrochloride
  • HY-110067
    VO-OHPic 675848-25-6 98%
    VO-OHPic is a reversible, noncompetitive and selective PTEN inhibitor with an IC50 of 46 nM. VO-OHPic attenuates apoptosis, adverse cardiac remodeling, and pro-inflammatory M1 macrophages in doxorubicin-induced cardiomyopathy. VO-OHPic inhibits autophagy.
    VO-OHPic
  • HY-110075
    Dexrazoxane monohydrochloride 1263283-43-7 98%
    Dexrazoxane monohydrochloride is the hydrochloride of Dexrazoxane (HY-B0581). Dexrazoxane can prevent or reduce cardiac damage and is an iron chelator and apoptosis inducer. Dexrazoxane has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities and inhibits ferroptosis.
    Dexrazoxane monohydrochloride
  • HY-112202
    GSK3395879 2215852-91-6 98%
    GSK3395879 is a selective and orally bioavailable transient receptor potential vanilloid-4 (TRPV4) antagonist with an IC50 of 1 nM for hTRPV4.
    GSK3395879
  • HY-112298
    DS88790512 2231089-95-3 98%
    DS88790512 is a potent, selective, and orally bioavailable TRPC6 inhibitor with an IC50 of 11 nM.
    DS88790512
  • HY-112441
    Prolyl Hydroxylase inhibitor 1 2205125-60-4 98%
    Prolyl Hydroxylase inhibitor 1 (Compound 15i) is an orally active hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor with an IC50 of 62.23 nM. Antianemia agent.
    Prolyl Hydroxylase inhibitor 1
  • HY-112704
    PDE5-IN-2 2244517-61-9 98%
    PDE5-IN-2 is a potent, highly selective, and orally active PDE5 inhibitor, with an IC50 of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC50s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity.
    PDE5-IN-2
  • HY-12176A
    Aliskiren hydrochloride 173399-03-6 98%
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hydrochloride is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hydrochloride can be used for the research of hypertension, cardiovascular diseases and cancer cachexia-.
    Aliskiren hydrochloride
  • HY-12176B
    Aliskiren fumarate 1196835-68-3 98%
    Aliskiren fumarate is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren fumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
    Aliskiren fumarate
  • HY-12323G
    ISX-9 (GMP) 832115-62-5 98%
    ISX-9 (Isoxazole 9) is a potent inducer of adult neural stem cell differentiation.
    ISX-9 (GMP)
  • HY-12378A
    BQ-123 TFA 98%
    BQ-123 TFA is a potent and selective endothelin A (ETA) receptor antagonist with an IC50 of 7.3 nM and a Ki of 25 nM. BQ-123 TFA inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension.
    BQ-123 TFA
  • HY-12807A
    FIPI hydrochloride 1781834-93-2 98%
    FIPI hydrochloride is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI hydrochloride regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI hydrochloride can be used in cancer research. In addition, FIPI hydrochloride can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function.
    FIPI hydrochloride
  • HY-128338
    CETP-IN-3 939391-31-8 98%
    CETP-IN-3 (Compound 13) is an small molecule inhibitor of the plasma glycoprotein cholesterol ester transfer protein (CETP), elevating HDL-C through inhibition of CETP. CETP-IN-3 for the CETP inhibitory activity in the scintillation proximity (SPA) and whole plasma assay (WPA) with IC50s of 0.002 μM and 0.06 μM, respectively.
    CETP-IN-3
  • HY-128889
    FXIa-IN-1 1803271-50-2 98%
    FXIa-IN-1 (compound EP-7041) is a potent β-lactam covalent heparin-derived factor XIa (fXIa) inhibitor.
    FXIa-IN-1
  • HY-13209C
    Ambrisentan sodium 1386915-48-5 98%
    Ambrisentan (BSF 208075) sodium is a selective and orally active ET type A receptor (ETAR) antagonist.
    Ambrisentan sodium
  • HY-134005
    ISIS 416858 1223657-78-0 98%
    ISIS 416858, a single-stranded antisense oligodeoxynucleotide, is a potent and selective inhibitor of FXI mRNA expression.
    ISIS 416858
  • HY-135283
    ABT-546 212481-66-8 98%
    ABT-546 (A-216546) is a potent, highly selective and active endothelin ETA receptor antagonist with a Ki of 0.46 nM for [125I]endothelin-1 binding to cloned human endothelin ETA. ABT-546 is >25,000-fold more selective for the ETA receptor than for the ETB receptor. ABT-546 blocks endothelin-1-induced arachidonic acid release and phosphatidylinositol hydrolysis with IC50 of 0.59 nM and 3 nM, respectively.
    ABT-546
  • HY-135390
    Hydroxy desmethyl Bosentan 253688-62-9 98%
    Hydroxy desmethyl Bosentan (Ro 64-105) is a Bosentan metabolism produced by the cytochrome P450 enzymes CYP2C9 and CYP3A4 in the liver. Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors with Ki of 4.7 nM and 95 nM in human SMC, respectively. Bosentan can be used in treatment of pulmonary arterial hypertension.
    Hydroxy desmethyl Bosentan
Cat. No. Product Name / Synonyms Application Reactivity